Showing results (201-210 of 208) with videos related to

Sort By:
Pageof 21
You have reached the last page of results.This site can display upto 208 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2024
Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP TrialVincent Camus, Catherine Thieblemont, Philippe Gaulard, et al.
Cancer Discovery|April 26, 2019
A Recurrent Activating Missense Mutation in Waldenström Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances ProliferationDamien Roos-Weil, Camille Decaudin, Marine Armand, et al.
Journal of Experimental & Clinical Cancer Research : CR|July 6, 2022
Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancersCapucine Baldini, Francois-Xavier Danlos, Andreea Varga, et al.
Blood Advances|March 3, 2025
Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphomaVincent Camus, Thierry Molina, Fabienne Desmots, et al.
The New England Journal of Medicine|September 6, 2018
Rituximab plus Lenalidomide in Advanced Untreated Follicular LymphomaFranck Morschhauser, Nathan H Fowler, Pierre Feugier, et al.
American Journal of Hematology|October 23, 2015
Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphomaMatthew J Maurer, Jean-Philippe Jais, Hervé Ghesquières, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2022
Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular LymphomaFranck Morschhauser, Loretta Nastoupil, Pierre Feugier, et al.
Blood|March 31, 2026
Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysisNicolas Gower, Pierre Feugier, Jason R Westin, et al.
Pageof 21